ArticleEBioMedicine2020
The transferability and evolution of NDM-1 and KPC-2 co-producing Klebsiella pneumoniae from clinical settings.
Article in EBioMedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 117 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
117 citing papers in PubMed.
- Genomic characterization of KPC-2 and NDM coproducing carbapenem-resistantMicrobiology spectrum · 2026Article
- Characteristics of an NDM-1-producing Klebsiella pneumoniae strain belonging to ST105.Antonie van Leeuwenhoek · 2026Article
- Molecular and phenotypic profiles of carbapenem- and third-generation cephalosporin-resistant Klebsiella pneumoniae isolates from the fecal microbiota of pediatric patients with COVID-19.BMC microbiology · 2026Article
- Mechanistic insights into phthalylsulfacetamide-induced restoration of meropenem bactericidal activity in NDM-1-positive Escherichia coli.BMC microbiology · 2026Article
- Clinically Significant Carbapenemases in Gram-Negative Pathogens: Molecular Diversity and Advances in β-Lactamase Inhibitor Therapy.Antibiotics (Basel, Switzerland) · 2026Review
- Within-host evolution drives the emergence of ceftazidime-avibactam resistance mediated by IncN plasmid-encodedMicrobiology spectrum · 2026Article
- Article
- Carbapenem resistance and hypervirulence iniScience · 2026Review
- First Report and Comprehensive Risk Index ofMicroorganisms · 2026Article
- Clinical characteristics and molecular evolution of ST11-KL64 carbapenem-resistant hypervirulentMicrobiology spectrum · 2026Article
- An aptamer-based "Gate-lock-key" strategy for metal-organic framework nanozyme-catalyzed colorimetric detection of multidrug-resistant bacteria.Mikrochimica acta · 2026Article
- First report of anMicrobiology spectrum · 2026Article
- Molecular characterization of a clinical ST145mSystems · 2026Article
- Epidemiological and genomic profiles of NDM-1-Producing ST25-KL2 carbapenem-resistant Klebsiella pneumoniae among pediatric patients in Hangzhou, China.BMC microbiology · 2026Article
- Carbapenemase-directed therapy: optimizing antibiotic combinations against carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Genomic and functional characterization of ST11-KL64 hypervirulence-associated carbapenem-resistantFrontiers in microbiology · 2026Article
- An ISFrontiers in microbiology · 2026Article
- Carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Combination of Ceftazidime-Avibactam and Aztreonam Effectively Treated Post-Cardiac Surgery Pneumonia Caused by Hypervirulent KPC- and NDM-ProducingInfection and drug resistance · 2026Article
- Eravacycline monotherapy and combination therapy against KPC-2- and NDM-1-co- producingFrontiers in microbiology · 2026Article
57 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEmergence of KPC-2 and NDM-1-coproducing carbapenem-resistant Klebsiella pneumoniae (KPC-2-NDM-1-CRKP) has escalated threat of CRKP to healthcare. Currently, only 4 isolates had been reported sporadically. It remains unclear how KPC-2-NDM-1-CRKPs emerged, and whether they are stable and have transmission capacity.
methodsPCR and Sanger sequencing was used to screen carbapenemase genes for 2057 CRKP isolates, to identify KPC-2-NDM-1-CRKPs. The clinical information of the patients was collected from medical records. Antimicrobial susceptibility, plasmid stability, plasmid conjugation and growth curve were measured. The whole genomes were sequenced on PacBio and Illumina platforms. Similar plasmids were searched against public database. Phylogenetic tree was built based on related genomes which carried similar plasmids, to infer the evolutionary history of KPC-2-NDM-1-CRKP.
findingsWe identified to date the largest cohort of 7 KPC-2-NDM-1-CRKPs. An increased incidence rate was observed. Plasmid transferability assay and phylogenic analysis suggested an evolutionary pathway that KPC-2-NDM-1-CRKP emerged from a KPC-2-CRKP progenitor which acquired another highly transferable bla
interpretationOur study extends our concern on KPC-2-NDM-1-CRKP about its high stability and non-inferior fitness, sheds light on the evolution of KPC-2-NDM-1-CRKP, strengthens the importance of continued surveillance on these isolates, and would improve clinical treatment and management.
fundingThis work was supported by National Natural Science Foundation for Distinguished Young Scholars of China (81625014) and NSFC-RCUK-MRC (81661138006).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.